Rapid Ebola Immunoassay From Corgenix Gains Authorization
This article was originally published in The Gray Sheet
Executive Summary
The firm's ReEBOV assay, which can deliver results within 15-25 minutes, is the first rapid test and immunoassay for the Ebola virus granted an emergency use authorization
by FDA.
You may also be interested in...
US FDA’s START Program Might See Expanded Funding If Pilot Meets Speed Goals
The program bringing Operation Warp Speed-like treatment to rare disease product development could expand if successful, but will require more employees and thus funding commitments from Congress and industry, CBER Director Peter Marks said.
Did Product Quality Decline While US FDA Inspectors Were Away?
Academics assert more should be done to restore pre-pandemic site-inspection activity levels, especially abroad, following analysis of 10 years of data on US FDA inspection trends, costs and resources published in Health Affairs.
Clinical Trial Diversity Planning Requires Prevalence-Based Enrollment Goals, Metrics For Gauging Success
Academic and industry experts caution against relying on historical enrollment numbers when setting new targets for under-represented populations and tout real-time monitoring dashboards, as well as a role for data monitoring committees, in assessing whether targets are being met in ongoing studies.